Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
2006-07-11
2006-07-11
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
C424S422000, C424S501000, C514S964000
Reexamination Certificate
active
07074432
ABSTRACT:
The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
REFERENCES:
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 3960757 (1976-06-01), Morishita et al.
patent: 4327039 (1982-04-01), Blum et al.
patent: 4389330 (1983-06-01), Tice et al.
patent: 4705651 (1987-11-01), Staibano
patent: 4746654 (1988-05-01), Breliere et al.
patent: 4922007 (1990-05-01), Kieczykowski et al.
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5019651 (1991-05-01), Kieczykowski
patent: 5196409 (1993-03-01), Breuer et al.
patent: 5312954 (1994-05-01), Breuer et al.
patent: 5412141 (1995-05-01), Nugent
patent: 5431920 (1995-07-01), Bechard
patent: 5583122 (1996-12-01), Benedict et al.
patent: 5618563 (1997-04-01), Berde et al.
patent: 5654010 (1997-08-01), Johnson et al.
patent: 5656297 (1997-08-01), Bernstein et al.
patent: 5667808 (1997-09-01), Johnson et al.
patent: 5674534 (1997-10-01), Zale et al.
patent: 5700485 (1997-12-01), Berde et al.
patent: 5711968 (1998-01-01), Tracy et al.
patent: 5716644 (1998-02-01), Zale et al.
patent: 5773477 (1998-06-01), MacLean et al.
patent: 5861168 (1999-01-01), Cooke et al.
patent: 5885973 (1999-03-01), Papapoulos et al.
patent: 5916597 (1999-06-01), Lee et al.
patent: 5922253 (1999-07-01), Herbert et al.
patent: 6080779 (2000-06-01), Gasper et al.
patent: 6117856 (2000-09-01), Binderman et al.
patent: 6123964 (2000-09-01), Asgharnejad et al.
patent: 6162929 (2000-12-01), Foricher et al.
patent: 6165513 (2000-12-01), Dansereau et al.
patent: 6399592 (2002-06-01), Whiteford
patent: 6558702 (2003-05-01), Dasch et al.
patent: 2002/0151876 (2002-10-01), Chan
patent: 709 085 (1996-05-01), None
patent: 839525 (1998-05-01), None
patent: WO 97/07788 (1997-03-01), None
Dunn, C.J. et al., “Demonstration of Novel Anti-Arthritic and Anti-Inflammatory Effects of Diphosphonates,”Journal of Pharmacology and Experimental Therapeutics, 266(3):1691-1698 (1993).
Van Gelder, J. M., et al., “In Vitro and in Vivo Effects of Tetrakisphosphonates on Bone Resorption, Tumor Osteolysis, Ectopic Calcification, and Macrophages,”Journal of Pharmaceutical Sciences, 86(3):283-289 (1997).
Nugent, R.A., et al., “Pyrazoline Bisphosphonate Esters as Novel Antiinflammatory and Antiarthritic Agents,”J. Med. Chem., 36:134-139 (1993).
D'Souza, M.J., et al., “Macrophage Depletion by Albumin Microencapsulated Clodronate: Attenuation of Cytokine Release in Macrophage-Dependent Glomerulonephritis,”Drug Development and Industrial Pharmacy, 25(5):591-596 (1999).
Nugent, R.A., et al., “Carbonyl-Containing Bisphosphonate Esters as Novel Antiinflammatory and Antiarthritic Agents,”J. Med. Chem., 37:4449-4454 (1994).
Hyvönen, P.M., and Kowolik, M.J., “Influence of Dichloromethylene Bisphosphonate on thein vitroPhagocytosis of Hydroxyapatite Particles by Rat Peritoneal Exudate Cells: An Electron Microscopic and Chemiluminescence Study,”Annals of the Rheumatic Diseases, 51:203-209 (1992).
Barbier, A., et al., “Studies on the Chronic Phase of Adjuvant Arthritis: Effect of SR 41319, A New Diphosphonate,”Annals of the Rheumatic Diseases, 45:67-74 (1986).
Van Rooijen, N., et al., “Transient Suppression of Macrophage Functions by Liposome-Encapsulated Drugs,”Trends in Biotechnology, 15:178-185 (1997).
Reginster, J.Y., et al., “Prevention of Postmenopausal Bone Loss by Tiludronate,”The Lancet, pp. 1469-1471, (1989, Dec. 23/30).
Bijvoet, O.L.M., et al., “APD in Paget's Disease of Bone,”Arthritis and Rheumatism, 23(10):1193-1204 (1980).
Francis, M.D., et al., “The Effects of Disodium Ethane-1-Hydroxy-1, 1-Diphosphonate on Adjuvant Induced Arthritis in Rats,”Calc. Tiss. Res., 9(20):109-121 (1972).
Flora, L., “Comparative Antiinflammatory and Bone Protective Effects of Two Diphosphonates in Adjuvant Arthritis,”Arthritis and Rheumatism, 22(4):340-346 (1979).
Francis, M.D., et al., “NE-58095: A Diphosphonate Which Prevents Bone Erosion and Preserves Joint Architecture in Experimental Arthritis,”Int. J. Tiss. Reac., XI(5):239-252 (1989).
Daoud, A.S., et al., “The Effect ot Ethane-1-Hydroxy-1,1-Diphosphonate (EHDP)on Necrosis of Atherosclerotic Lesions,”Atherosclerosis, 67:41-48 (1987).
Camilleri, J.P., et al., “The Effect of Free and Liposome-Encapsulated Clondronate on the Hepatic Mononuclear Phagocyte System in the Rat,”Clin. Exp. Immunol., 99(2):269-275 (1995).
Biewenga, J., et al., “Macrophage Depletion in the Rat After Intraperitoneal Administration of Liposome-Encapsulated Clodronate: Depletion Kinetics and Accelerated Repopulation of Peritoneal and Omental Macrophages by Administration of Freund's Adjuvant,”Cell Tissue Res., 280(1):189-196 (1995).
Van Rooijen, N., et al., “Depletion and Repopulation of Macrophages in Spleen and Liver of Rat After Intravenous Treatment with Liposome-Encapsulated Dichloromethylene Diphosphonate,”Cell Tissue Res., 260(2):215-222 (1990).
Delemarre, F.G.A., et al., “Repopulation of Macrophages in Popliteal Lymph Nodes of Mice After Liposome-Mediated Depletion,”Journal of Leukocyte Biology, 47(3):251-257 (1990).
Storm, T., et al., “Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal Osteoporosis,” New England Journal of Medicine, 322(18):1265-1271 (1990).
Ralston, S.H., et al., “A Double Blind Placebo-Controlled Trial of Diphosphonate (APD) Therapy in Rheumatoid Arthritis-Preliminary Results,”Calcified Tissue, Supplement to vol. 42, p. A23, Abstract No. 90 (1988).
Markusse, H.M., et al., “Bisphosphonates in Collagen Arthritis,”Rheumatology International, 9(6):281-283 (1990).
Vyavahare, et al., “Synergism of Calcium-Ethanehydroxybisphosphonate (CaEHBP) and FeCl3: Controlled Release Polymers for Preventing Calcification of Bioprosthetic Aortic Wall,”Journal of Controlled Release, 34:97-108, (1995).
Weidenauer, U., et al., “Microencapsulation of hydrophilic drug substances1 using biodegradable polyesters. Part 1: Evaluation of different techniques for the encapsulation of Pamidronate di-sodium salt”,J. Microencapsulation, 20(4): 509-524 (2003).
Perugini, P. et al., “Long-term Release of Clodronate from Biodegradable Microspheres,” AAPS PharmSciTech, 2(3) article 10:1-9 (2001).
Dasch James R.
Riley M. Gary I.
Alkermes Controlled Therapeutics Inc.
Hamilton Brook Smith & Reynolds P.C.
Russel Jeffrey Edwin
LandOfFree
Method of modifying the release profile of sustained release... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of modifying the release profile of sustained release..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of modifying the release profile of sustained release... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602099